Key Takeaways Novo Nordisk's blockbuster weight-loss drug, Wegovy, received Food and Drug Administration approval to treat a ...

The Food and Drug Administration approved the weight loss drug Wegovy to treat an increasingly prevalent liver disease on ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through ...

The launch marked Danish drugmaker Novo Nordisk's debut on the continent, ramping up competition with rival Eli Lilly.

Wegovy is the brand name for semaglutide, the same molecule found in Ozempic, the type 2 diabetes treatment, which some doctors have been prescribing off-label for weight loss.

Novo Nordisk stock rose after good news from the FDA on Wegovy—it’s popular weight-loss drug which has the same active ...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.

Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa on Thursday, marking its debut in Africa ...

Wegovy, or semaglutide, is the newest weight loss medication to receive regulatory approval. Wegovy was recently approved, on 4 June 2021, by the US Food and Drug Administration (FDA) for the ...

Ozempic and Wegovy are the same drug, but they are FDA-approved and prescribed for different conditions. Ozempic is used in the treatment of Type 2 diabetes, while Wegovy is prescribed for weight loss ...

Second-quarter sales of the blockbuster drug soared 67% on year, despite millions of U.S. patients using generic unbranded ...